Dermsquared Scheduled Maintenance, Thursday Feb 29, 6:30am to 8:30am EST

2023 Fall Clinical Virtual Grand Rounds

2023 Virtual Grand Rounds Session 16: December 6, 2023 - JAK Inhibitors and Wound Care Update

About

Fall Clinical Virtual Grand Rounds consist of regularly scheduled CME sessions on a variety of dermatological diseases, delivered by the top experts in dermatology. Please join us for this week's session:

Wednesday, December 6, 2023

8 PM ET / 5 PM PT

JAK Inhibitors: Who is Afraid of the Big Black Box?

What's New in Wound Care

Availability

In order to ensure educational material is relevant, educational materials will expire after a certain time period. This course will be available for the following dates:

Release Date:

December 7, 2023

Expiration Date:

December 7, 2024

Learning Objectives

At the completion of this activity, participants should be better able to:

  • Evaluate data concerning side effects of JAK inhibitors

  • Assess new treatments and their on label and off label use

  • Understand the benefits of single use Negative Pressure Wound Therapy

  • Utilize novel skin grafting techniques in the clinical practice

Intended Audience
This activity has been designed for dermatologists, dermatology physician assistants, dermatology nurse practitioners, and other providers involved in the care of patients.
Faculty
James
James Del Rosso, DO

Adjunct Clinical Professor, Dermatology
Touro University Nevada
Henderson, NV

Robert
Robert Kirsner, MD

Chairman and Harvey Blank Professor
Dr. Phillip Frost Department of Derm & Cutaneous Surgery 
Miller School of Medicine - University of Miami
Miami, FL

Mark
Mark Lebwohl, MD

Dean for Clinical Therapeutics
Waldman Professor
Chairman Emeritus
Kimberly and Eric J. Waldman Department of Dermatology
Icahn School of Medicine at Mount Sinai
New York, NY

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Institute for Continuing Healthcare Education and CMEsquared. The Institute is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement

The Institute for Continuing Healthcare Education designates this live and enduring activity for a maximum of 1 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosures & Disclaimers

CONFLICTS OF INTEREST/DISCLOSURES

In accordance with the ACCME Standards for Commercial Support, balance, independence, objectivity, and scientific rigor are ensured in all CME activities. This requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with any ineligible companies. In addition, the content of this material has been approved by an independent peer reviewer. 

Disclosures are as follows:

James Q. Del Rosso, DO

Grant/Research Support: Aclaris, Amgen, Anaptys Bio, Arcutis, Athenex, Bausch (Ortho), Biorasi, Botanix, Brickell, Cara Therapeutics, Cassiopea, Dermavant, EPI Health, Galderma, Genentech, Incyte, Janssen, LEO, Lilly, Novan, Pfizer, Ralexar, Sanofi Genzyme Regeneron, Sol-Gel, SUN, Vyne

Consultant: Abbvie, Aclaris, Almirall, Amgen, Arcuits, Bausch (Ortho), Biofrontera, Biopharmx, Blue Creek, BMS, Cassiopea, Dermata, Dermavant, Encore, EPI Health, Evoummune, Ferndale, Galderma, Incyte, Jem Health, LEO, La Roche Posay, Lilly, MC2, Novan, Pfizer, Sanofi Genzyme Regeneron, Sente, Sol-Gel, Sonoma, SUN, UCB, Verrica, Vyne

Speakers’ Bureau or Honoraria: Abbvie, Aclaris, Almiral, Amgen, Bausch (Ortho), Biofrontera, Encore, EPI Health Ferndale, Galderma, Genentech, Jem Health, LEO, Lilly, Pfizer, Sanofi Genzyme Regeneron, SUN, UCB, Verrica, Vyne

Robert S. Kirsner, MD

Advisory Board: Abbvie, Molnklycke, Organogenesis, Pfizer, Urgo

Grant/Research Support: Hoth

Mark Lebwohl, MD

Grant/Research Support: Abbvie, Amgen, Arcutis, Avotres, Boehringer Ingelheim, Cara Therapeutics, Dermavant Sciences, Eli Lilly, Incyte, Inozyme, Janssen Research & Development, LLC, Novartis, Ortho Dermatologics, Regeneron, and UCB, Inc.

Consultant: AnaptysBio, Arcutis, Inc., Arena Pharmaceuticals, Aristea Therapeutics, Avotres Therapeutics, BioMX, Boehringer-Ingelheim, Brickell Biotech, Cara Therapeutics, Castle Biosciences, Corevitas, Dermavant Sciences, Evommune, Inc., Facilitation of International Dermatology Education, Hexima Ltd., Meiji Seika Pharma, Mindera, National Society of Cutaneous Medicine, New York College of Podiatric Medicine, Pfizer, Seanergy, SUN Pharma, Verrica, and Vial.

The planners have disclosed that they have no relevant financial relationships with any Ineligible Company in the past 24 months.  

The Institute discloses that all relevant conflicts have been satisfactorily mitigated.


Dermsquared

The leading solutions platform for dermatology professionals to elevate patient care.

Contact Us

Support

Subscribe now

Enter your email to get the latest updates.

© 2024 dermsquared | All Rights Reserved